SEARCH

SEARCH BY CITATION

REFERENCES

  • Abi-Dargham A., Laruelle M., Casanova M. F., Weinberger D. R., and Kleinman J. E. (1990) [3H]Quipazine binding sites in human limbic system. Soc. Neurosci. Abstr. 16, 1298.
  • Ashby C. R., Edwards E., Harkins K. L., and Wang R. Y. (1989) Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: a microiontophoretic study. Eur. J. Pharmacol. 166, 583584.
  • Barnes J. M., Barnes N. M., Costall B., Ironside J. W., and Naylor R. J. (1989) Identification and characterisation of 5-hydroxy-tryptamine3 recognition sites in human brain tissue. J. Neurochem. 53, 17871793.
  • Blandina P., Goldfarb J., Craddock Royal B., and Green J. P. (1989) Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J. Pharmacol. Exp. Ther. 251, 803809.
  • Bradley P. B., Engel G., Fenuik W., Fozard J. R., Humphrey P. P. A., Middlemiss D. N., Mylecharane E. J., Richardson B. P., and Saxena P. R. (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 6, 563576.
  • Costall B., Domeney A. M., Naylor R. J., and Tyers M. B. (1987a) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. 92, 881894.
  • Costall B., Domeney A. M., Naylor R. J., and Tyers M. B. (1987b) The antipsychotic effect of GR38032F, a selective antagonist of 5-HT3 receptors in central nervous system. Br. J. Pharmacol. 90, 89P.
  • Dumuis A., Bouhelal R., Sebben M., and Bockaert J. (1988) A 5-HT receptor in the central nervous system, positively coupled to adenylate cyclase, is antagonized by ICS 205930. Eur. J. Pharmacol. 146, 187188.
  • Fludzinski P., Evard D. A., Bloomquist W. E., Lacefield W. B., Pfeifer W., Jones N. D., Deeter J. B., and Cohen M. L. (1987) Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5-HT3 receptor. J. Med. Chem. 30, 15351537.
  • Gaddum J. H. and Picarelli Z. P. (1957) Two kinds of tryptamine receptor. Br. J. Pharmacol. Chemother. 12, 323328.
  • Gehlert D. R., Gackenheimer S. L., Wong D. T., and Robertson D. W. (1991) Localization of 5-HT3 receptors in the rat brain using [3H]-LY278584. Brain Res. 553, 149154.
  • Gozlan H., Kidd E., Bouchelet I., Lanfumey L., Levy J. C., and Hamon M. (1991) [3H]-R-Zacopride binds with a high affinity to a new site in addition to 5-HT3 receptors. Soc. Neurosci. Abstr. 17, 720.
  • Hagan R. M., Butler A., Hill J. M., Jordan C. C., Ireland S. J., and Tyers M. B. (1987) Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur. J. Pharmacol. 138, 303305.
  • Imperato A. and Angelucci L. (1989) 5-HT3 receptors control dopamine release in the nucleus accumbens of the freely moving rats. Neurosci. Lett. 101, 214217.
  • Kilpatrick G. J., Jones B. J., and Tyers M. B. (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330, 746748.
  • Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with Folin phenol reagent. J. Biol. Chem. 193, 263274.
  • McKernan R. M., Quirk K., Jackson R. G., and Ian Ragan C. (1990) Solubilisation of the 5-hydroxytryptamine3 receptor from pooled rat cortical and hippocampal membranes. J. Neurochem. 54, 924930.
  • McPherson G. A. (1985) Analysis of radiobinding experiments. A collection of computer programs for the IBM PC. J. Pharmacol. Methods 14, 213228.
  • Milburn C. M. and Peroutka S. J. (1989) Characterization of [3H]-quipazine binding to 5-hydroxytryptamine3 receptors in rat brain membranes. J. Neurochem. 52, 17871792.
  • Munson P. and Rodbard D. (1980) LIGAND: a versatile computerized approach for characterization of ligand binding systems. Anal. Biochem. 107, 220239.
  • Nelson D. R. and Thomas D. R. (1989) [3H]-BRL 43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem. Pharmacol. 38, 16931695.
  • Newcomer J. W., Faustman W. O., Roth B., Bierley R. A., Moses J. A., and Csernansky J. G. (1990) Zacopride in schizophrenia: a single-blind 5-HT3 antagonist trial. Soc. Neurosci. Abstr. 16, 752.
  • Peroutka S. J. (1988) Species variations in 5-HT3 recognition sites labeled by [3H]-quipazine in the central nervous system. Naunyn Schmiedebergs Arch. Pharmacol. 338, 472475.
  • Peroutka S. J. and Hamik A. (1988) [3H]-Quipazine labels 5-HT3 recognition sites in rat cortical membranes. Eur. J. Pharmacol. 148, 297299.
  • Richardson B. P., Engel G., Donatsch P., and Stadler P. A. (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316, 126131.
  • Sorensen S. M., Humphreys T. M., and Palfreyman M. G. (1989) Effect of acute and chronic MDL-73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur. J. Pharmacol. 163, 115118.
  • Waeber C., Hoyer D., and Palacios J. M. (1989) 5-Hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]-ICS 205–930. Neuroscience 31, 393400.
  • Watling K. J., Aspley S., Swain C. J., and Saunders J. (1988) [3H]-Quaternised ICS 205–930 labels 5-HT3 receptor binding sites in rat brain. Eur. J. Pharmacol. 149, 397398.
  • Weiland G. A. and Molinoff P. B. (1981) Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 29, 313330.
  • Wong D. T., Robertson D. W., and Reid L. R. (1989) Specific [3H]-LY278584 binding to 5-HT3 recognition sites in rat cerebral cortex. Eur. J. Pharmacol. 166, 107110.